Further, using cell-based assays on in vitro models of PCa and clinical data, we demonstrated that FK866 has the potential to be repurposed as novel candidate drugs for treating lethal PCa, particularly in PCa models of Taxane and/or AR-inhibitor drug resistance and cancer stemness. This evidence concerns the gene AR and posterior cortical atrophy.